Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Apr;25(4):433–438. doi: 10.1111/j.1365-2125.1988.tb03326.x

Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on blood pressure in hypertensive patients known to respond to beta 1-adrenoceptor antagonists.

O J Robb 1, J Webster 1, J C Petrie 1, J D Harry 1, J Young 1
PMCID: PMC1387804  PMID: 2898256

Abstract

1. The selective beta 2-adrenoceptor antagonist ICI 118,551, 50 mg orally given thrice daily, did not lower blood pressure in hypertensive patients known to respond to therapy with atenolol or propranolol. 2. This dosage regimen resulted in a small decrease in supine heart rate which might represent partial beta 1-adrenoceptor antagonism by ICI 118,551. 3. The results suggest that beta 2-selective antagonism does not play a role in the hypotensive action of beta-adrenoceptor antagonists.

Full text

PDF
433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold J. M., O'Connor P. C., Riddell J. G., Harron D. W., Shanks R. G., McDevitt D. G. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol. 1985 May;19(5):619–630. doi: 10.1111/j.1365-2125.1985.tb02689.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bilski A. J., Halliday S. E., Fitzgerald J. D., Wale J. L. The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol. 1983 May-Jun;5(3):430–437. doi: 10.1097/00005344-198305000-00013. [DOI] [PubMed] [Google Scholar]
  3. Brodde O. E., Karad K., Zerkowski H. R., Rohm N., Reidemeister J. C. Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding. Circ Res. 1983 Dec;53(6):752–758. doi: 10.1161/01.res.53.6.752. [DOI] [PubMed] [Google Scholar]
  4. Brown M. J., Brown D. C., Murphy M. B. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414–1419. doi: 10.1056/NEJM198312083092303. [DOI] [PubMed] [Google Scholar]
  5. Dahlöf B., Andrén L., Svensson A., Hansson L. Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade. J Hypertens Suppl. 1983 Dec;1(2):112–115. [PubMed] [Google Scholar]
  6. Gardner M. J., Altman D. G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):746–750. doi: 10.1136/bmj.292.6522.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. O'Donnell S. R., Walduck K. How beta2-selective is the adrenoceptor antagonist drug, IPS 339? J Pharm Pharmacol. 1981 Apr;33(4):223–225. doi: 10.1111/j.2042-7158.1981.tb13762.x. [DOI] [PubMed] [Google Scholar]
  8. Tattersfield A. E., Cragg D. J. Effect of ICI 118551 on bronchial beta-adrenoceptor function and exercise heart rate in normal man. Br J Clin Pharmacol. 1983 Dec;16(6):587–590. doi: 10.1111/j.1365-2125.1983.tb02226.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Webster J., Hawksworth G. M., Barber H. E., Jeffers T. A., Petrie J. C. Withdrawal of long-term therapy with atenolol in hypertensive patients. Br J Clin Pharmacol. 1981 Aug;12(2):211–214. doi: 10.1111/j.1365-2125.1981.tb01202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES